Long-Term Remission Under Combined, Systematic Therapy in Advanced or Metastatic Soft Tissue Sarcoma: A Case Report

被引:0
作者
Wang, Ping [1 ]
Xia, Lei [1 ,2 ,3 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 2, Dept Canc Ctr, Chongqing 401336, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Tianjin Key Lab Radiat Med & Mol Nucl Med, Inst Radiat Med, Tianjin 300110, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin 300060, Peoples R China
关键词
Soft Tissue Sarcoma; Anlotinib; PD-1; Inhibitor; Doxorubicin Liposome; Radiation Therapy; OPEN-LABEL; PHASE-II; MULTICENTER; DOXORUBICIN; RADIATION;
D O I
10.1166/jbn.2023.3606
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Soft tissue sarcomas (STSs) are rare and heterogeneous tumors with limited treatment options for advanced stages. In this case series, we present two patients with advanced STSs who were treated with a sequential maintenance therapy strategy of chemotherapy, anti-angiogenesis, PD-1 inhibitors, and local radiotherapy. The first patient had leiomyosarcoma, and the second patient had alveolar soft part sarcoma (ASPS). Both patients had negative PD-L1 results and high tumor mutation burden (TMB). The first patient progressed after multiline therapy and radiotherapy, while the second patient had advanced disease at diagnosis. The treatment regimen for both patients included doxorubicin and anlotinib, followed by maintenance therapy with anlotinib and tislelizumab. Both patients achieved long-term remission, with the second patient benefiting for 58 months. This systemic treatment approach offers a new option for personalized and precise treatment of advanced STSs. The success of this approach highlights the potential of combining chemotherapy, anti-angiogenesis, PD-1 inhibitors, and local radiotherapy for the treatment of advanced STSs.
引用
收藏
页码:1098 / 1103
页数:6
相关论文
共 13 条
[1]   An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas† [J].
Agulnik, M. ;
Yarber, J. L. ;
Okuno, S. H. ;
von Mehren, M. ;
Jovanovic, B. D. ;
Brockstein, B. E. ;
Evens, A. M. ;
Benjamin, R. S. .
ANNALS OF ONCOLOGY, 2013, 24 (01) :257-263
[2]   Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions [J].
Filatenkov, Alexander ;
Baker, Jeanette ;
Mueller, Antonia M. S. ;
Kenkel, Justin ;
Ahn, G-One ;
Dutt, Suparna ;
Zhang, Nigel ;
Kohrt, Holbrook ;
Jensen, Kent ;
Dejbakhsh-Jones, Sussan ;
Shizuru, Judith A. ;
Negrin, Robert N. ;
Engleman, Edgar G. ;
Strober, Samuel .
CLINICAL CANCER RESEARCH, 2015, 21 (16) :3727-3739
[3]   Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity [J].
Lee, Won Suk ;
Yang, Hannah ;
Chon, Hong Jae ;
Kim, Chan .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2020, 52 (09) :1475-1485
[4]  
Liu J., 2022, CLIN CANCER RES, V28, P3473, DOI DOI 10.1158/1078-0432.CCR-22-0871
[5]   A perspective review on impact and molecular mechanism of environmental carcinogens on human health [J].
Malik, Sumira ;
Prasad, Shilpa ;
Kishore, Shristi ;
Kumar, Abhishek ;
Upadhyay, Vineet .
BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, VOL 37, ISSUE 2 (2021), 2021, 37 (02) :178-207
[6]   Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study [J].
Savina, Marion ;
Le Cesne, Axel ;
Blay, Jean-Yves ;
Ray-Coquard, Isabelle ;
Mir, Olivier ;
Toulmonde, Maud ;
Cousin, Sophie ;
Terrier, Philippe ;
Ranchere-Vince, Dominique ;
Meeus, Pierre ;
Stoeckle, Eberhard ;
Honore, Charles ;
Sargos, Paul ;
Sunyach, Marie-Pierre ;
Le Pechoux, Cecile ;
Giraud, Antoine ;
Bellera, Carine ;
Le Loarer, Francois ;
Italiano, Antoine .
BMC MEDICINE, 2017, 15
[7]   Cancer statistics, 2023 [J].
Siegel, Rebecca L. ;
Miller, Kimberly D. ;
Wagle, Nikita Sandeep ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2023, 73 (01) :17-48
[8]   Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial [J].
Tap, William D. ;
Wagner, Andrew J. ;
Schoffski, Patrick ;
Martin-Broto, Javier ;
Krarup-Hansen, Anders ;
Ganjoo, Kristen N. ;
Yen, Chueh-Chuan ;
Razak, Albiruni R. ;
Spira, Alexander ;
Kawai, Akira ;
Le Cesne, Axel ;
Van Tine, Brian A. ;
Naito, Yoichi ;
Park, Se Hoon ;
Fedenko, Alexander ;
Papai, Zsuzsanna ;
Soldatenkova, Victoria ;
Shahir, Ashwin ;
Mo, Gary ;
Wright, Jennifer ;
Jones, Robin L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (13) :1266-1276
[9]   Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial [J].
Tap, William D. ;
Papai, Zsuzsanna ;
Van Tine, Brian A. ;
Attia, Steven ;
Ganjoo, Kristen N. ;
Jones, Robin L. ;
Schuetze, Scott ;
Reed, Damon ;
Chawla, Sant P. ;
Riedel, Richard F. ;
Krarup-Hansen, Anders ;
Toulmonde, Maud ;
Ray-Coquard, Isabelle ;
Hohenberger, Peter ;
Grignani, Giovanni ;
Cranmer, Lee D. ;
Okuno, Scott ;
Agulnik, Mark ;
Read, William ;
Ryan, Christopher W. ;
Alcindor, Thierry ;
Garcia del Muro, Xavier F. ;
Budd, G. Thomas ;
Tawbi, Hussein ;
Pearce, Tillman ;
Kroll, Stew ;
Reinke, Denise K. ;
Schoffski, Patrick .
LANCET ONCOLOGY, 2017, 18 (08) :1089-1103
[10]   Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial [J].
Tap, William D. ;
Jones, Robin L. ;
Van Tine, Brian A. ;
Chmielowski, Bartosz ;
Elias, Anthony D. ;
Adkins, Douglas ;
Agulnik, Mark ;
Cooney, Matthew M. ;
Livingston, Michael B. ;
Pennock, Gregory ;
Hameed, Meera R. ;
Shah, Gaurav D. ;
Qin, Amy ;
Shahir, Ashwin ;
Cronier, Damien M. ;
Ilaria, Robert, Jr. ;
Conti, Ilaria ;
Cosaert, Jan ;
Schwartz, Gary K. .
LANCET, 2016, 388 (10043) :488-497